Onemednet Corp

Onemednet Corp(ONMD)股票分析

$0.568

-0.004 (-0.73%)收盤時

Loading chart…
High
0.580
Open
0.574
VWAP
0.57
Vol
110.09K
Mkt Cap
Low
0.564
Amount
62.81K
EV/EBITDA, TTM
0.00

OneMedNet Corporation is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (RWD), through its OneMedNet iRWD solution. The Company provides solutions within the clinical image archives of healthcare providers. It de-identifies, searches, and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to providers. By leveraging this extensive federated provider network, together with technology and in-house clinical expertise, the Company meets the rigorous RWD life science requirements. OneMedNet iRWD offers advanced technology, clinical expert curation, and service. Medical imaging and associated clinical data are indexed at each network site using artificial intelligence (AI)/ machine learning (ML) technology. This includes EHR, radiology, cardiology, lab, path, and others. In addition to its customized data packages, it also offers regulatory-grade, pre-packaged imaging RWD sets.

AI analysis of Onemednet Corp (ONMD)

sell

Onemednet Corp is not a good buy right now due to its current price of 0.58, which is significantly down 52.46% year-to-date. The stock shows a low RSI of 35.949, indicating it is oversold, but the negative catalysts, including a 19.42% decline over the last 20 days, suggest continued weakness. Additionally, the company has a concerning net income loss of -2,172,000 USD in the most recent quarter, which raises significant risk for investors.

估值指標

The current forward P/E ratio for Onemednet Corp (ONMD) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
高估
0.00
低估
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
高估
0.00
低估
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
高估
0.00
低估
0.00

Alphio AI Price Scenarios for ONMD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ONMD

$0.77

情境價格

B

Base

Base · 50%ONMD

$0.68

情境價格

B

Bear

Bear · 25%ONMD

$0.57

情境價格

Whales holding ONMD

D

Discovery Capital Management, LLC

+ HoldingONMD

-6.94%

3M Return

事件時間軸

2026-07-28 (ET)

09:30:00

OneMedNet Signs Agreement to Supply $11.5M Healthcare Data

2026-07-01 (ET)

18:00:00

OneMedNet Files to Sell 11.68M Shares of Common Stock

2026-03-18 (ET)

09:00:00

OneMedNet Announces Strategic Collaboration with Navidence

2026-02-27 (ET)

09:00:00

OneMedNet Launches RWD Platform, Accelerates Subscription Growth

2026-02-26 (ET)

08:50:00

OneMedNet Partners with ViuHealth for Strategic Collaboration

資訊

ONMD FAQ — answered by Alphio AI

OneMedNet Corporation is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (RWD), through its OneMedNet iRWD solution. The Company provides solutions within the clinical image archives of healthcare providers. It de-identifies, searches, and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to providers. By leveraging this extensive federated provider network, together with technology and in-house clinical expertise, the Company meets the rigorous RWD life science requirements. OneMedNet iRWD offers advanced technology, clinical expert curation, and service. Medical imaging and associated clinical data are indexed at each network site using artificial intelligence (AI)/ machine learning (ML) technology. This includes EHR, radiology, cardiology, lab, path, and others. In addition to its customized data packages, it also offers regulatory-grade, pre-packaged imaging RWD sets. It operates in the Industrials sector (COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH industry).

Onemednet Corp is not a good buy right now due to its current price of 0.58, which is significantly down 52.46% year-to-date. The stock shows a low RSI of 35.949, indicating it is oversold, but the negative catalysts, including a 19.42% decline over the last 20 days, suggest continued weakness. Additionally, the company has a concerning net income loss of -2,172,000 USD in the most recent quarter, which raises significant risk for investors.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始